Last updated: January 11, 2022
Sponsor: First Affiliated Hospital of Fujian Medical University
Overall Status: Active - Recruiting
Phase
N/A
Condition
Myasthenia Gravis (Chronic Weakness)
Muscular Dystrophy
Spinal Muscular Atrophy
Treatment
N/AClinical Study ID
NCT05187260
MRCTA,ECFAH of FMU [2021]489
Ages < 50 All Genders Accepts Healthy Volunteers
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Patients genetically confirmed 5q SMA including types I, II and III, who are planningto initiate treatment with SPINRAZA® (nusinersen) as part of their clinical care plan.
- Non-5q SMA patients undergoing clinical standard lumbar puncture
- Non-SMA subjects including Asymptomatic carriers of SMA, relatives of SMA patients andcarriers, and patients undergoing clinical standard lumbar puncture
- Participants or Parent(s)/legal guardian(s) willing and able to complete the informedconsent process
Exclusion
Exclusion Criteria:
- Contraindication for lumbar puncture
- Inability to access intrathecal space for nusinersen injection
Study Design
Total Participants: 1000
Study Start date:
January 01, 2022
Estimated Completion Date:
January 31, 2024
Study Description
Connect with a study center
Department of Neurology, Peking Union Medical College Hospital
Beijing, Beijing 100010
ChinaActive - Recruiting
Department of Neurology, First Affiliated Hospital Fujian Medical University
Fuzhou, Fujian 350005
ChinaSite Not Available
Department of Pediatrics, Fujian Medical University Union Hospital
Fuzhou, Fujian 350001
ChinaActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.